GAITHERSBURG, Md., Aug. 14 /PRNewswire-FirstCall/ -- MedImmune, Inc. announced today that it has promoted Edward T. Mathers to executive vice president, corporate development and venture. In this role, he is responsible for the company’s licensing and business development activities and is a key leader of the company’s MedImmune Ventures, Inc. team evaluating investment opportunities.
“Since joining MedImmune in 2002, Ed has been an instrumental part of implementing our long-term plan to build one of the best product portfolios in the industry,” said David M. Mott, chief executive officer and president. “Ed’s work in expanding our pipeline through in-licensing and acquisition opportunities has complemented our increased investment in internally driven research and development. During the past 18 months alone, Ed and his team have successfully completed 16 strategic transactions, including in- licensings, collaborations and a company acquisition. In the same timeframe, our ventures team, which he helps lead, has completed 14 strategic investments in promising young companies that have the potential to bring meaningful financial and scientific rewards to MedImmune in the future. Ed is also a key member of our executive management team, critically involved in strategic direction and operations of the company.
“I look forward to continuing to work with Ed and his team as we strive to achieve our long-term goals to become one of the most productive and profitable biotech companies in the industry while contributing meaningfully to the advancement of human health,” Mott concluded.
Prior to joining MedImmune, Mr. Mathers was vice president of marketing and corporate licensing and acquisitions at Inhale Therapeutic Systems. Previously, he enjoyed a successful 15-year career at Glaxo Wellcome, Inc., holding a number of increasingly responsible positions in sales and marketing. Mr. Mathers began his career as a researcher at Ortho Pharmaceuticals Corporation, a division of Johnson & Johnson. Mr. Mathers holds a bachelor’s degree in chemistry from North Carolina State University.
About MedImmune, Inc.
MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 2,300 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company’s website at http://www.medimmune.com.
This announcement contains, in addition to historical information, certain “forward-looking statements” regarding MedImmune’s long-term, strategic objectives. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change current expectations and could cause actual outcomes and results to differ materially from current expectations. In addition to risks and uncertainties discussed in MedImmune’s filings with the U.S. Securities and Exchange Commission, no assurance exists that development efforts for the company’s pipeline programs will succeed, that these programs will receive required regulatory approval or that, even if regulatory approval is received, products resulting from these programs will be commercially successful. MedImmune undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise except as may be required by applicable law or regulation.
MedImmune, Inc.
CONTACT: Media: Jamie Lacey, +1-301-398-4035 or Clarencia Stephen,+1-301-398-4073; or Investors: Peter Vozzo, +1-301-398-4358 or BeatricePierre, +1-301-398-4905, all of MedImmune, Inc.
Web site: http://www.medimmune.com//
